Form 4: Entrada Therapeutics CFO Kory James Wentworth Sells Shares Under 10b5-1 Trading Plan

Entrada Therapeutics' CFO, Kory James Wentworth, sold 3,195 shares of common stock at an average price of $14.971 per share on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 9, 2024, Kory James Wentworth, the Chief Financial Officer of Entrada Therapeutics, Inc. (TRDA), sold 3,195 shares of the company's common stock.
• The sale was executed at a weighted average price of $14.971 per share.
• The transactions were carried out under a Rule 10b5-1 trading plan adopted on March 15, 2024.
• Following the reported transaction, Wentworth beneficially owns 76,486 shares of Entrada Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, as it simply reports factual information about a share sale under a pre-arranged trading plan.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency to investors regarding the trading activities of company executives. The use of a 10b5-1 trading plan suggests that the sales were pre-planned and not based on any inside information at the time of the transaction.

Stakeholder Impact

• The sale of shares by the CFO could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 trading plan mitigates concerns about insider information being used for personal gain.

Key Dates